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Abstract
Background: Despite its cardiotoxicity doxorubicin is widely used for the treatment of paediatric malignancies.
Current treatment regimens appear to be suboptimal as treatment strategies vary and do not follow a clear
pharmacological rationale. Standardisation of dosing strategies in particular for infants and younger children is
required but is hampered by scarcely defined exposure-response relationships. The aim is to provide a rational
dosing concept allowing for a reduction of variability in systemic therapy intensity and subsequently unforeseen
side effects.
Methods: Doxorubicin plasma concentrations in paediatric cancer patients were simulated for different treatment
schedules using a population pharmacokinetic model which considers age-dependent differences in doxorubicin
clearance. Overall drug exposure and peak concentrations were assessed. Simulation results were used to support a
three round Delphi consensus procedure with the aim to clarify the pharmacological goals of doxorubicin dosing
in young children. A group of 28 experts representing paediatric trial groups and clinical centres were invited to
participate in this process.
Results: Pharmacokinetic simulations illustrated the substantial differences in therapy intensity associated with
current dosing strategies. Consensus among the panel members was obtained on a standardised a priori dose
adaptation that individualises doxorubicin doses based on age and body surface area targeting uniform drug
exposure across children treated with the same protocol. Further, a reduction of peak concentrations in very young
children by prolonged infusion was recommended.
Conclusions: An approach to standardise current dose modification schemes in young children is proposed. The
consented concept takes individual pharmacokinetic characteristics into account and involves adaptation of both
the dose and the infusion duration potentially improving the safety of doxorubicin administration.
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Background
Since their introduction to chemotherapy in the 1960s
anthracyclines have gained widespread use in the treat-
ment of solid and haematological malignancies. Today,
roughly 60% of children with cancer receive anthracy-
clines, most commonly doxorubicin (DOX). Anthracy-
clines significantly increase event-free survival in Ewing’s
sarcoma and a better antitumor efficacy is suggested for
acute lymphoblastic leukaemia (ALL) [1]. However, a
well-known drawback of this class of cytostatics is the
induction of progressive chronic cardiotoxicity which is
associated with cardiomyopathy, congestive heart failure
and elevated mortality [2]. The risk of irreversible car-
diac damage has been associated in particular with the
cumulative lifetime anthracycline dose and age which
exposes the youngest patients to the highest risk [3–5].
Much attention has been paid to measures seeking to
prevent adverse cardiac effects, which, inter alia, include
cardioprotective agents such as dexrazoxane as well as
liposomal anthracyclines [6, 7]. Administration of weekly
split-doses rather than one large dose as well as pro-
longed continuous infusions were among the most stud-
ied strategies. Essentially, these approaches rely on the
assumption that drug exposure (expressed as area under
the concentration-time curve (AUC)) is the most im-
portant determinant of antitumor efficacy and that re-
duced peak concentrations (cmax) mitigate the toxic
cardiac effect of anthracyclines without affecting their
antitumor activity [8]. After 50 years of clinical use a
plethora of studies in adult patients have been per-
formed supporting the rationale of prolonged continu-
ous infusion or split-dose schedules to reduce
cardiotoxicity [8–10]. For paediatrics, however, the situ-
ation is less clear due to the paucity of well-designed
randomized trials [11–14]. Our understanding of the
consequences of pharmacokinetic (PK) parameters such
as AUC and cmax for both toxicity and efficacy in paedi-
atrics still remain insufficient. It has been suggested that
the positive effect of continuous infusion seen in adult
patients is attributed to a reduction of the cardiac
anthracycline concentration [8]. However, one might
argue that in children with a developing heart, longer ex-
posure due to prolonged infusion might be just as toxic
as high peak concentrations.
Underscoring the high demand on more information
on the PK and safety of DOX in paediatrics, the Euro-
pean Medicines Agency put DOX on their 2007 ‘priority
list on studies for off-patent medicinal products’ sup-
porting the conduct of further trials (doc. Ref. EMEA/
197972/2007, London, June 2007). Based on data from
the EPOC-MS-001-Doxo trial Völler et al. demonstrated
that the DOX clearance normalized to body surface area
(BSA) is significantly lower in children below the age of
3 years compared to older children [15]. Besides age and
BSA, other covariates such as genetic polymorphisms in
genes responsible for drug transport and metabolism or
the tumour entity did not have an effect on DOX PK.
Though the physiological basis is unclear, the results of
the EPOC trial raise the question whether the reduction
of clearance and its effect on individual systemic therapy
intensity is of direct clinical importance and should im-
pact dosing recommendations.
When looking at current treatment regimens in paedi-
atrics, one is faced with a multitude of DOX doses,
infusion times and instructions for dose modifications
(see Additional file 1 for a selection of current protocols)
[16, 17]. Protocols for children have evolved over time
and are rather based on empirical grounds than follow-
ing a sound pharmacological rationale. This becomes
particularly apparent with the large variability of dose
modification schemes that are used for the youngest
children. Dose modifications applied to infants and
young children below a certain age or body weight are
justified by the higher risk of late cardiac abnormalities
in this patient group, yet age- and/or body weight-based
boundaries and conversion rules from BSA-based dosing
to body weight-based dosing are seemingly arbitrary. Ex-
emplarily, the CWS-SoTiSaR guidance recommends
switching from BSA-based dosing to body weight-based
dosing in children below 1 year or weighing less than 10
kg (see Additional file 1). A further dose reduction to
67% of the body weight-based dose is intended for chil-
dren below 6months. In contrast, according to the
NHL-BFM 2012 registry children below the age of 1 year
should receive 75% of the BSA-based dose and children
below 6months 67% of the BSA-based dose. Obviously,
these dose modifications result in large discrepancies of
the DOX dose across children of different age but
treated for the same cancer. Furthermore, as soon as a
child reaches a particular age−/body weight boundary
there will be a sudden increase in the DOX dose.
Undoubtedly, with increasing numbers of childhood
cancer survivors the prevention of cardiotoxic late ef-
fects must be given top priority. This also implies that
the current practice of DOX administration needs to be
critically questioned. Both factors described here, age-
dependent differences of the DOX clearance as well as
empirical dose modifications will affect the therapy in-
tensity experienced by the individual child with un-
known influence on therapy efficacy and safety. A
standardised dosing strategy for young children which
adequately reflects individual PK characteristics would
therefore be highly desirable. As pointed out by Völler
et al. the DOX population PK model provides a tool to
develop more rationale alternative dosing strategies [16].
However, as described in the beginning a well-defined
target PK parameter on which to base such a dosing
strategy is still lacking. In this paper we will propose an
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approach how standardising dosing strategies for young
children could be achieved. At first, we will visualise the
influence of empirical dose modifications and age-
dependent PK differences on therapy intensity (AUC
and cmax) for a number of selected treatment protocols
thereby demonstrating the shortcomings of current ap-
proaches. Secondly, we will clarify the goals of future
dosing recommendations in young children. For the lat-
ter, a Delphi consensus procedure among expert paedi-
atric oncologists was conducted. In perspective, the
approach described here will provide the possibility to
validate a common dosing strategy in young children
across the different study groups taking into account the
specific dose intensity for each tumour entity.
Methods
Pharmacokinetic simulations
To visualize the impact of current dosing recommenda-
tions along with age-dependent differences in PK on
drug exposure and peak concentrations Monte Carlo
simulations were carried out using a population PK
model published by Völler et al. [15]. The model was
built upon PK data from 94 patients from the EPOC-
MS-001-Doxo trial (see Additional file 3 for a short de-
scription of the patients). This patient cohort was con-
sidered to represent typical paediatric cancer patients.
Simulations of children aged 0–18 years with demo-
graphics taken from WHO and CDC growth charts were
performed and DOX doses and infusion times from a se-
lection of currently applied paediatric treatment regi-
mens were analysed (see Additional file 1) [18].
Individuals on the 5th, 50th or 95th percentile of body
height and weight were simulated. Model parameters
were fixed for simulations to the final parameter esti-
mates of the EPOC patient population. To display the
typical course of AUC and cmax for a median child inter-
individual and intra-individual variability were set to
zero. Simulations including inter- and intra-individual
variability were performed to display the remaining vari-
ability that cannot be explained by age and BSA. This
variability represents the uncertainty associated with any
model-based prediction. Each individual was simulated
1000 times.
In order to illustrate the effect of a standardized
model-based dose calculation rule on drug exposure, ob-
served AUC values for 94 patients from the EPOC co-
hort were compared with hypothetical, dose-adjusted
AUC values. Calculation of dose-adjusted AUC values
was based on a dose adaptation previously described by
Völler et al. [16]. This dose adaptation takes individual
age and BSA into account, as these parameters were
identified as predictive covariates for DOX PK [15]. As
reference AUC value for the suggested dose adaptation
the AUC of an 18-year-old boy was chosen. For the
purpose of this paper, we will refer to this reference
value as ‘target AUC’. Based on the model-predicted
clearance CL18 years for a typical 18-year-old boy with
median demographics (eq. 1), this target AUC18 years was
determined as 344 μg·L− 1·h for a reference dose of 10
mg·m− 2 (1278 μg·L− 1·h for a reference dose of 1 mg·kg− 1
in case of body weight-based dosing). An adjusted DOX
dose was obtained for each patient from the EPOC co-
hort according to eqs. 1 and 2. Firstly, the model-
predicted clearance was estimated considering each pa-
tient’s age and BSA (eq. 1). Secondly, the adjusted DOX
dose was calculated (eq. 2), where Dose18 is the absolute
DOX dose for the typical 18-year-old boy specified by
the respective treatment regimen.
CLmodel−predicted ¼ 9:26 1þ BSA−0:77ð Þ1:30ð Þ 1þ AGE5:32
 0:286 !
ð1Þ
Doseind ¼ Dose18 yearsCLmodel−predictedCL18 years ð2Þ
Based on the observed and adjusted DOX doses, ob-
served and dose-adjusted AUC values were calculated
according to eq. 3 with CLEPOC denominating the empir-
ical Bayesian clearance estimates derived from the
EPOC-MS-001-Doxo data.
AUC ¼ Dose=CLEPOC ð3Þ
To allow comparison across different treatment regi-
mens and to illustrate deviations from the target, ob-
served and dose-adjusted AUC values were normalised
to the regimen-specific target AUC. Bias and precision
were calculated for both groups as median prediction
error and median absolute prediction error according to
Sheiner and Beal [19]. The probability to attain a target
range of 80–125% was calculated for both groups. The
range of 80–125% around the target AUC was adopted
from bioequivalence standards [20].
Data and statistical analysis
Monte Carlo simulations were carried out in NON-
MEM® version 7.3 [21]. R version 3.5.0 [22] and RStudio
version 1.1.456 [23] were used for graphical representa-
tion of simulation results and statistical analysis. Non-
parametric Wilcoxon signed rank test was performed on
continuous data and McNemar’s chi-squared test was
performed on paired nominal data. A p value < 0.05 was
deemed statistically noticeable. Confidence intervals for
the median were calculated using the function ‘quanti-
leCI’ provided by the R package ‘jmuOutlier’ which cal-
culates exact confidence intervals on quantiles based on
the binomial test.
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Delphi consensus procedure
Overall 28 paediatric oncologists were invited to partici-
pate in a three round Delphi consensus procedure.
While the main focus of the Delphi procedure was to es-
tablish a consensus on the goals of hitherto protocol-
specific DOX dose modifications in young children, a
couple of further questions were asked covering general
goals of DOX administration as well as additional as-
pects that were raised by the panel members during the
first round of the Delphi process. A detailed description
of the methodology can be found in Additional file 4.
Results
Visualising the therapy intensity achieved with current
protocols
We performed simulations for three selected treatment
protocols to illustrate the discrepancies in systemic ther-
apy intensity achieved with current treatment protocols.
For each protocol the simulations visualise the joint im-
pact of current dose modification schemes and age-
dependent PK differences on AUC and cmax. As outlined
by Fig. 1 exemplarily for three treatment regimens, sub-
stantial differences in drug exposure and peak concen-
trations have to be expected across children aged 0–18.
In very young children who are subject to dose reduc-
tions these may lead to particularly sharp steps in ther-
apy intensity. To illustrate this in more detail we will use
the example of a child treated according to the CWS-
SoTiSaR guidance (dose: 20 mg·m− 2, infusion time: 3 h).
Here, the standard BSA-based dose is reduced in chil-
dren < 6months to 67% of the body weight-based dose
and in children 6–12 months or < 10 kg to 100% of the
body weight-based dose (see Additional file 1). As the
ratio of body weight to BSA is lower in infants than in
older children moving from BSA- to body weight-based
dosing leads to a reduction of the administered DOX
dose. In this case, simulated typical AUC and cmax are
lowest in neonates (AUC = 507 μg·L− 1·h, cmax =
56 μg·L− 1) and increase towards a maximum in children
slightly above 1 year of age (AUC = 1002 μg·L− 1·h, cmax =
138 μg·L− 1) which highlights the impact of the dose
modification. Despite the decrease in clearance in young
children, using this dose reduction scheme the lowest
therapy intensity is experienced by the youngest chil-
dren. Of note, typical AUC and cmax for children 2
months and younger are extrapolated as the youngest
child included in the EPOC-MS-001-Doxo trial was 2.5
months old. Due to the increase in DOX clearance with
growing age, simulated typical AUC decreases from its
maximum 1002 μg·L− 1·h in a child slightly above 1 year
of age to 688 μg·L− 1·h at the age of 18. Similarly, how-
ever less pronounced, typical cmax decreases from
138 μg·L− 1 to 117 μg·L− 1.
As simulations of typical AUC and cmax values simpli-
fies the real-life situation with large inter-individual vari-
ability of DOX PK, taking this variability into account
gives us a more genuine impression of variability in
AUC and cmax in children. It becomes evident that,
Fig. 1 DOX AUC (a) and cmax (b) across the age range from 0 to 18 years. Typical AUC and cmax values were simulated for children on the 50th
percentile of body height and weight for three selected treatment regimens. Underlying DOX doses were adjusted as specified by the respective
regimen. NB Registry 2016 N4 (standard dose: 15 mg·m− 2, 0.5 h): reduction to 100% of the body weight-based dose in children < 12months or <
10 kg; CWS-SoTiSaR (20 mg·m− 2, 3 h): reduction to 67% of the body weight-based dose in children < 6months and reduction to 100% of the
body weight-based dose in children ≥6 months but ≤10 kg; AIEOP-BFM ALL 2017 (30 mg·m− 2, 1 h): reduction to 67% of the BSA-based dose in
children < 6months and reduction to 75% of the BSA-based dose in children 6–12months. The grey boxes mark the areas of the curve where
doses were reduced. For a child on the 50th percentile of body height and weight the threshold for dose reduction is reached at an age of 14
months exceeding a body weight of 10 kg (NB Registry 2016 N4, CWS-SoTiSaR) or 12 months (AIEOP-BFM ALL 2017), respectively
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irrespective of schedule- and age-dependent variations, a
substantially broad distribution of individual AUC and
cmax has to be considered due to the high variability in
PK that cannot be sufficiently explained by age and BSA
(Fig. 2a, b). For a 2-year-old child treated according to
the CWS-guidance, the 5th percentile of simulated AUC
Fig. 2 DOX AUC and cmax depending on age (a, b), body composition (c, d), and treatment regimen (e, f). For (a, b) children on the 50th
percentile of body height and weight were simulated and for (c, d) children aged 1 year were simulated. The DOX dose was adopted from the
CWS-guidance and doses were reduced in children < 6months to 67% of the body weight-based dose and in children 6–12 months or < 10 kg
to 100% of the body weight-based dose (see Additional file 1). For (e, f) a median 2-year-old child was simulated (for doses and infusion times
see Additional file 1). To display the remaining inter-individual variability that cannot be attributed to the influence of age or body surface area
simulations were replicated 1000 times
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values is 565 μg·L− 1·h and the 95th percentile is
1588 μg·L− 1·h. Corresponding percentiles for simulated
cmax values are 83 μg·L
− 1 and 207 μg·L− 1.
As a result of conversion rules from BSA-based dosing
to body weight-based dosing, therapy intensity will fur-
ther differ among infants of the same age but heteroge-
neous in body composition depending on the specific
regimen-defined boundaries. For example, simulated
median doxorubicin AUC and cmax differ more than
30% between a one-year old child on the 95th percentile
of body weight who already receives the full BSA-based
dose according to the CWS-guidance and a child on the
5th or 50th percentile of body weight who still receives
the body-weight-based dose (Fig. 2 c, d).
A comparison of simulated AUC and cmax following a
single drug administration between selected treatment
regimens is displayed in Fig. 2 (e, f). Besides the dose,
the duration of infusion determines peak concentrations
leading to large differences between treatment regimens.
Though the dose is lower in the NB 2016 N4 regimen
(15 mg·m− 2) compared to the CWS-guidance (20
mg·m− 2) median peak concentrations simulated for a 2-
year-old child are more than 3 times higher due to the
difference in infusion time (30 min vs. 3 h).
Can we make it better?
A standardized approach to modify the DOX dose in
young children can be derived from the population PK
model for DOX. A dosing method that aims to achieve
more uniform AUC levels across the age range has been
described by our group before [16]. In the present study,
we assessed the impact of the suggested dosing method
on drug exposure for the 94 children of the EPOC pa-
tient population (Fig. 3). Application of this dosing algo-
rithm allows to achieve a defined target AUC without
relevant bias (− 2.5%, 95% confidence interval -8–3%),
however, variability in drug exposure is still substantial
underlined by the small decrease in precision between
observed (21%, 95% confidence interval 18–23%) and
hypothetical, dose-adjusted AUC values (17%, 95% confi-
dence interval 13–19%) (p < 0.05). The percentage of
AUC attaining the range of 80–125% around the target
AUC was 58.5% for the observed AUC and 69.1% for
dose-adjusted AUC values. This difference was not sta-
tistically noticeable.
Defining a common consensus for DOX dosing concepts
in children
To strengthen the rationale for dose modifications in
young children we conducted a Delphi consensus pro-
cedure in which 11 expert paediatric oncologists partici-
pated (see Additional file 2 for the 2nd round
questionnaire). Those experts represented large paediat-
ric study groups as well as clinical centres.
Two main conclusions can be drawn from this consen-
sus procedure. First, standardisation of dose modifica-
tions in young children should be based on the aim of
uniform drug exposure across the age range. Secondly,
peak levels should be additionally reduced in the youn-
gest patients. Therefore, treatment strategies for children
should adapt both the dose and the duration of infusion.
As a further conclusion, future DOX-containing regi-
mens for children should be designed such that
extremes in therapy intensity are avoided which encour-
ages attempts to further study the concentration-
response-relationships of DOX in order to select the
most appropriate doses and schedules. A detailed de-
scription of the results of the Delphi procedure is pre-
sented in Additional file 4.
Discussion
Among childhood cancer survivors, cardiac disease is
the leading non-malignant cause for morbidity and mor-
tality [24]. As the vast majority of children diagnosed
with cancer are currently cured [25], the prevention of
treatment-related toxicities plays a key role. For DOX
and other anthracyclines the relationship of PK mea-
sures (e.g. AUC, cmax) and treatment outcome has not
been definitively established. Nevertheless, the reduction
of variability in treatment intensity holds promise to bet-
ter balance tumour efficacy and the risk of toxicity, in
Fig. 3 Comparison of observed AUC from 94 patients from the
EPOC-MS-001-Doxo trial and dose-adjusted AUC. Adjusted DOX
doses were derived from a model-based dose calculation rule. AUC
values were calculated based on the post-hoc clearance estimates
taken from the NONMEM analysis and normalised to the target AUC
of a typical 18-year-old boy. The dashed red line indicates the target
AUC of 100% and dotted red lines indicate a range of 80–125%
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particular late cardiac effects. Seemingly arbitrary
thresholds for dose modification and conversion rules as
part of empirically-derived treatment regimens along
with age-dependent differences in individual PK substan-
tially contribute to this variability. Protocol optimisation
is needed and might offer the possibility to increase the
safety of DOX administration.
A population PK model-based strategy to adapt DOX
doses in young children has been described by our group
before [16]. A weak point of this method, however, is
the lack of evidence for the target PK parameter. Adapt-
ing the DOX dose with the aim to achieve more uniform
drug exposure across the age range considers that AUC
is presumably the most relevant determinant for therapy
efficacy [26]. It neglects, however, the higher organ tox-
icity of DOX in young children and the role of the peak
concentration for cardiac toxicity [3, 8–10]. In a situ-
ation when definite clinical evidence is lacking a Delphi
consensus procedure may help to sharpen the rationale
and pharmacological goals of DOX dose modifications
in children with cancer. In contrast to open group dis-
cussions this approach permits collecting individual
opinions and transforming opinions into a group con-
sensus without being influenced by a single opinion
leader [27]. Though evidence is scarce, the Delphi pro-
cedure allowed clarifying the pharmacological goals of
dose modifications and formulating a standardised dos-
ing concept, based on the collective knowledge and
opinion of clinical experts. It should be clearly stated
that collective opinion must not be erroneously confused
with scientific evidence and should not be seen as indis-
putable fact. A Delphi procedure does not create new
knowledge but rather seeks to make optimal use of
already existing knowledge [27].
However, with the consented a priori dose adaptation
a consistent strategy applicable to all treatment regi-
mens has become available. The Delphi panel con-
firmed the initially proposed concept which
individualises absolute DOX doses based on patient
characteristics (age and BSA) that are predictive for
DOX PK. Aiming at uniform drug exposure among
children treated according to the same protocol thereby
appears to be most reasonable as systemic drug expos-
ure has been widely used as a surrogate marker for dose
adaptations [28]. An appropriate dosing equation is
available based on the population PK model for DOX
(cf. formulas 1 & 2 in the “Methods” section) [16]. In
this way optimised treatment regimens may allow for a
rational choice of the DOX dose in paediatrics, ideally
improving the safety of DOX application. As an exten-
sion of the dosing concept described in [16], the ex-
perts also recommended an additional reduction of
peak levels in very young children by prolonged infu-
sion, thus taking into account the presumed influence
of peak levels on cardiotoxicity and the higher cardiac
risk of very young patients. In conclusion, modifications
of treatment strategies in young children should there-
fore be based on two aspects, adjustment of the dose
and of the infusion duration.
As a prerequisite for the proposed dosing concept the
target AUC that should serve as reference needs to be
specified. In our example we used the AUC expected for
a ‘standard’ 18-year-old boy (i.e. an adult patient) as a
reference (Fig. 3), as this seems to be straightforward.
However, other targets might be even more appropriate.
For instance, a target AUC based on the median clear-
ance of a representative patient population has been
used for renal function-based carboplatin dosing [29].
Apart from that, the consented prolongation of infusion
time in younger children as a measure to reduce peak
concentrations might be opposed by clinical practicabil-
ity (i.e. practicability in an ambulatory care setting) and
patient convenience. In addition, the exact influence of
infusion time on peak concentrations also requires fur-
ther investigation.
Constraining the range of DOX doses and infusion
times that are applied in current protocols may offer an
opportunity to prevent extreme AUC values and, maybe
more important, peak concentrations. As described
above, a plethora of studies investigated the potentially
beneficial impact of prolonged infusion (i.e. lower peak
concentration) on cardiac outcome [8–11, 14]. Based
on a systematic review of the existing literature, Loeffen
and colleagues recommended a DOX infusion duration
of at least 1 h in paediatric cancer patients [30]. How-
ever, this conclusion does not take into account the ad-
ministered dose and its impact on cmax. Additionally,
some evidence is available pointing to an increased risk
of heart failure with a higher maximal anthracycline
dose within 1 week [31]. The avoidance of very short
infusion times on the one hand or very high DOX doses
on the other hand thus represents a potential measure
to reduce the risk of long-term cardiac side effects. This
has been unanimously consented by the expert panel
but some disagreement arose from the question
whether target ranges could be uniformly defined
across different tumour types. In contrast to the large
variety in DOX administration, there is no data that
clearly demonstrate that different tumour entities in-
deed need specific peak concentrations or drug expos-
ure. Yet, in multi-agent combination chemotherapy
regimens adequate DOX therapy intensity will be influ-
enced by the particular combination of chemotherapeu-
tic drugs. Obviously, more research on the dose-
concentration-effect relationships in different tumour
types is needed to support the establishment of
pharmacologically meaningful thresholds and the selec-
tion of the most appropriate doses and schedules.
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The approach presented herein underlines the value of
population PK modelling for treatment optimisation.
The DOX population PK model was used to illustrate
the complex interplay of dose modifications and PK rela-
tionships. Moreover, it provides an opportunity to trans-
late the consented dosing goals into alternative dosing
algorithms. It has to be mentioned that the validity of
the model-based approach is limited by the small num-
ber of patients below the age of 1 year recruited in the
EPOC-MS-001-Doxo trial (N = 4) with the youngest
child being 2.5 months old. Thus, uncertainties of
model-based predictions are highest in this age group.
Similar is true for highly obese paediatric patients. For a
routine use of any model-based dosing recommendation
two requirements are thus mandatory. Firstly, it is neces-
sary to further validate the population PK model by
assessing its predictive performance in a new patient
population which should include relevant numbers of in-
fants and young children [32]. Secondly, the consented
dosing concept needs to be validated in a prospectively-
designed clinical trial assessing its suitability to target a
predefined drug exposure.
One may criticize that the Delphi expert panel was ra-
ther small to draw meaningful conclusions. However,
standards for panel sizes have not yet been established
and in the past, Delphi studies have been performed with
virtually any panel size. With similar trained experts a
small expert panel may be used with sufficient confidence
[33]. Despite the small number of participants, agreement
among the experts was strong with relatively little vari-
ation for most of the questions. The obtained consensus
reflects the perspectives of both relevant paediatric study
groups and clinical centres. Nonetheless, further discus-
sion with clinical experts on the findings and potential
implementations is highly welcome.
As suggested by Fig. 3, a relatively small reduction in
variability of drug exposure can be expected though indi-
vidualisation of the DOX dose with respect to age and
BSA. Large variability is a long-known characteristic of
DOX PK. In adults, substantial inter-patient variations of
AUC despite standardisation of the dose based on BSA
were observed and differences in dose-normalised peak
concentrations of more than 10-fold between children
with ALL were reported in a study by Frost et al. [34–36].
Adaptive administration of chemotherapeutics based on
plasma concentration measurements could provide an op-
portunity to further reduce variability in drug exposure.
Individual PK parameters can be easily predicted based on
a few plasma concentration measurements using a Bayes-
ian forecasting approach [28]. It has been shown before
that adaptive dosing of chemotherapeutics can result in a
narrower and more accurate exposure range compared
with standard BSA-based dosing and can positively impact
therapeutic outcome [37, 38]. However, in the past several
studies revealed unpredictable differences in individual
DOX PK between consecutive administrations [34, 39]. In
a study by Hempel et al. in paediatric ALL and non-
Hodgkin lymphoma patients intra-individual deviations in
peak concentration ranged from 3.5 to 198% [39]. In ac-
cordance, population PK analysis of data from the EPOC-
MS-001-Doxo trial found high intra-individual variability
on the central volume of distribution [15]. Due to the high
intra-individual variability Hempel et al. concluded that
dose individualisation based on monitoring of peak con-
centrations will not be feasible. In contrast, in a popula-
tion PK analysis in adults and children older than 3 years
intra-individual variability of DOX clearance accounted
only for 13% [40]. As drug elimination might be less af-
fected from intra-individual variability adaptive dosing ap-
proaches aiming to better control variability in drug
exposure could indeed be promising. In fact, within the
Delphi process the expert panel members acknowledged
that therapeutic drug monitoring might be beneficial at
least for defined paediatric patient populations.
Nevertheless, pre-analytical variability affects the un-
certainties of pharmacokinetic models and model-based
predictions. Further, the implementation of drug moni-
toring and adaptive dosing approaches in clinical routine
is hampered by considerable technical effort and logis-
tical requirements. The development of miniaturised
monitoring tests and their delivery to the point-of-care
is crucial to overcome these limitations [41].
Conclusions
Making use of the collective opinion of clinical experts
the pharmacological goals of DOX dose modifications
have been specified. The consented a priori dose adapta-
tion provides a consistent alternative to the huge diver-
sity of current dosing recommendations for small
children thus offering the chance to improve safety of
this potent anticancer drug in the most vulnerable pa-
tient population. In perspective, the possibility is given
to validate a common dose calculation rule in young
children across the different study groups taking into ac-
count the specific dose intensity for each tumour entity
and allowing for a unique drug exposure across age
Table 1 Key aspects that need to be considered for clinical
implementation of model-based dosing recommendations
1 Development and implementation of miniaturised bedside analytics
in order to minimise pre-analytical variability and facilitate drug
monitoring
2 External validation of pharmacokinetic models and, if appropriate,
further refinement in order to assess the predictive power and
decrease the uncertainties of model predictions
3 Development of optimised limited sampling strategies to keep the
burden of blood sampling for children at a minimum
4 Clinical validation of model-based dosing recommendations in a pro-
spectively designed clinical trial
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within children of the same tumour entity. Nevertheless,
the translation of any model-based dosing recommenda-
tion for DOX into clinical practice requires consider-
ation of several key aspects (Table 1).
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